COVID-19, Olfaction Disorders
Conditions
Keywords
anosmia, smell disorder, COVID-19, MRI
Brief summary
Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients. This study aimed to detect these disturbances among positive COVID-19 patients (symptom not initially highlighted by the patient and not sought by caregivers) in order to allow early management of olfactory and gustatory dysfunction.
Detailed description
Several medical teams have recently shown that disturbances of smell and taste are common and can be a precursor and even an isolated sign of COVID-19 involvement. Preliminary results suggest the presence of clinical MRI abnormalities, particularly in the olfactory bulbs in anosmic patients with COVID-19. Anosmia and taste disturbance are early warning signs that could be important in improving the detection and diagnosis of COVID-19, and also in monitoring disease. In addition, disturbances in smell and taste could be an aid in establishing the prognosis of the clinical course of the viral disease. The question of olfactory recovery is also fundamental. To date, we do not know the possibilities of recovery from COVID-19 post viral anosmia. ENT exams, olfactometry and MRI are proposed to study these phenomena.
Interventions
DIAGNOSTIC_TESTENT exam
ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
DIAGNOSTIC_TESTOlfactometry
Olfactometry test using odorous pens (Sniffin's stick test).
DIAGNOSTIC_TESTBrain MRI
Brain MRI focused on the olfactory bulbs (3 teslas).
Sponsors
Hôpital Raymond Poincaré
Hopital Foch
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 or over * Patient with or without a sense of smell diagnosed with a positive COVID-19 PCR test by nasopharyngeal swab in one of the investigation centers * Patient who has already undergone cerebral MRI and olfactometry, as part of their routine care, within 3 days of being diagnosed with COVID-19+ or who agrees to undergo cerebral MRI and olfactometry within 3 days of being diagnosed with COVID-19+. * Patient who signed a consent form * Patient being affiliated to a Health Insurance plan
Exclusion criteria
* History of chronic rhino-sinusitis with or without polyp (s) * History of major craniofacial trauma that led to loss of smell * History of chronic sense of smell * Diagnosis of Parkinson's disease or Alzheimer's disease * Refusal to perform the 3 MRIs * Refusal to participate in the study * Pregnant, parturient or lactating woman * Patient with contraindications to performing MRI * Patient not speaking or understanding French * Patient deprived of liberty or under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by MRI on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. | initial examination | Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner. |
| To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. | initial examination | Sniffin' test score (T threshold score, D discrimination score, I identification score). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on MRI in in COVID-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months. | initial examination, 6 week to 2 months, 6 to 9 months | Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner at initial examination, between 6 weeks and 2 months and between 6 and 9 months. |
| To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients. | initial examination, 6 week to 2 months, 6 to 9 months | Sniffin' test score (T threshold score, D discrimination score, I identification score). |
Countries
France
Outcome results
None listed